MD Anderson, Daiichi Sankyo Partner to Develop AML Treatments

The University of Texas MD Anderson Cancer Center and Daiichi Sankyo said today they plan to develop novel therapies for acute myeloid leukemia (AML) through a multiyear collaboration whose value was not disclosed.MD Anderson and Daiichi Sankyo said their collaboration will focus on carrying out “numerous” clinical trials assessing combination regimens that use several investigational compounds from Daiichi Sankyo’s pipeline and multiple other treatments.The collaboration plans